Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

Heart failure study in mice: blocking one molecule eased heart damage

☕ Includes a question for the family ↓

Heart failurePart of a story we are following · 5 articles · See every update
Must attribute with link to: www.ptpioneer.com Stability ball squats outdoors 2
Must attribute with link to: www.ptpioneer.com Stability ball squats outdoors 2Photo: PTPioneer / Wikimedia Commons, CC BY 2.0

If you or someone you love lives with heart failure, you know how few options there are for turning it around. A new study in mice offers a hopeful early lead. It has not been tested in people yet.

In a study in mice, blocking a molecule called circ-ZNF609 eased the heart damage that comes with pressure overload, a common path to heart failure, and it also eased damage that was already there. This is lab work. No people were treated, so it is a clue for future research and not a treatment you can ask for.

What is heart failure, and why does this matter?

Heart failure does not mean the heart has stopped. It means the heart cannot pump as well as the body needs. Over time, the heart muscle can thicken and stiffen. Scientists call this “cardiac remodeling.”

The authors of the study note that there are currently no effective ways to reverse heart failure. Most care today aims to manage it. That is why researchers look for the molecular switches that drive remodeling. If one of them can be turned down, it could one day become a new kind of treatment.

How the study worked

Researchers studied mice whose hearts were put under pressure by a small surgical narrowing of the main artery leaving the heart, which causes heart damage over several weeks. They also tested heart muscle cells and scar-forming cells in the lab. The work was published on November 19, 2026 in Cell Reports Medicine, and because it was done in mice and cells, it cannot yet tell us whether the same approach would be safe or work in people.

What they found

Four weeks after the heart was put under pressure, the mice had higher levels of circ-ZNF609 in heart tissue, in heart muscle cells and in the cells that form scar tissue. This molecule is a small, ring-shaped piece of RNA, a kind of messenger inside cells.

When the researchers silenced circ-ZNF609 using a tool called shRNA, the heart damage from the pressure was reduced.

Then came the more interesting test. The team used a second tool, called an hfCas13x-crRNA system, to block circ-ZNF609 in mice that already had established heart thickening. Blocking it eased that existing damage too. That matters because a real treatment would need to help people whose hearts are already affected.

In lab dishes, blocking circ-ZNF609 also did two helpful things:

  • It reduced the enlargement of heart muscle cells.
  • It reduced the change of fibroblasts, which are support cells, into myofibroblasts, the cells that build stiff scar tissue.

The team also worked out part of the chain of events. circ-ZNF609 teams up with a protein called YTHDF3, and together they raise the level of another protein called ZEB1. Blocking circ-ZNF609 lowered ZEB1. Turning down YTHDF3 alone also protected the mouse hearts from remodeling.

What does this mean for you?

The useful takeaway is that scientists found a specific target and showed that hitting it can ease heart damage in mice, even after the damage has started. That is the kind of groundwork new treatments are built on.

Many findings in mice do not carry over to people. The next steps would be more animal work and safety testing before any human trial. Current advice for heart failure does not change because of this study.

What you can do today

If you have heart failure, keep doing what your care plan says, and write down one question to bring to your next visit, such as “What can I do day to day to keep my heart stronger?” Your care team knows your situation best.

For clinicians and researchers

Design: Preclinical study in mice with transverse aortic constriction (TAC), assessed at 4 weeks, plus in vitro cardiomyocyte and cardiac fibroblast experiments. Interventions: shRNA silencing and an hfCas13x-crRNA RNA-targeting system. Sample sizes are not given in the abstract.

Main result: circ-ZNF609 was upregulated after TAC. Its silencing attenuated TAC-induced cardiac remodeling, and hfCas13x-crRNA inhibition attenuated established cardiac hypertrophy. circ-ZNF609 interacts with YTHDF3 in an m6A-dependent manner to regulate ZEB1. No effect sizes are reported in the abstract.

Main limitation: Animal model (TAC in mice) with in vitro cells; findings may not translate to human heart failure, and no safety or delivery data in humans are reported.

Open question: Whether circ-ZNF609 inhibition is safe and effective in larger animals and humans with heart failure, and whether the circ-ZNF609/YTHDF3/ZEB1 axis operates in human myocardium.

Talk about it at home

Your heart is a muscle that works like a pump, squeezing all day long to push blood around your body. In this study, scientists found a tiny molecule inside heart cells that acts a bit like the volume knob on a speaker: when it is turned up too loud, the heart muscle becomes thick and stiff. When the researchers turned that knob down in mice, their hearts did better.

Try it at home

Look up together why scientists so often study mice before they study people, and find out what mice and people have in common inside their bodies.

Keep exploring

Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. Heart failure study in mice: blocking one molecule eased heart damage. Mongevity. Published November 21, 2026. Accessed November 22, 2026. https://mongevity.science/heart/2026/11/heart-failure-mice-circ-znf609-reverse-remodeling/
Vancouver
Mongevity Desk. Heart failure study in mice: blocking one molecule eased heart damage [Internet]. Mongevity; 2026 Nov 21 cited 2026 Nov 22]. Available from: https://mongevity.science/heart/2026/11/heart-failure-mice-circ-znf609-reverse-remodeling/
APA
Mongevity Desk. (2026, November 21). Heart failure study in mice: blocking one molecule eased heart damage. Mongevity. https://mongevity.science/heart/2026/11/heart-failure-mice-circ-znf609-reverse-remodeling/
For your website
<a href="https://mongevity.science/heart/2026/11/heart-failure-mice-circ-znf609-reverse-remodeling/">Heart failure study in mice: blocking one molecule eased heart damage</a>

Free to share or quote with credit and a link.

Questions and answers

Can this treat heart failure in people now?
No. The study was done in mice and in lab-grown cells. It has not been tested in people, so it is not a treatment you can get.
What is circ-ZNF609?
It is a small, ring-shaped piece of RNA found in cells. In the mouse hearts, levels of it went up after the heart was put under pressure.
Did the approach work on damage that had already started?
In mice, yes. Blocking circ-ZNF609 eased heart thickening that was already established.
Should I change my heart failure care because of this?
No. Current advice does not change. Keep following your care plan and ask your care team any questions you have.

Sources

  1. Cell Rep Med: Therapeutic targeting of circ-ZNF609 attenuates cardiac remodeling by modulating the expression of ZEB1 (PMID 43057240 · DOI 10.1016/j.xcrm.2026.103172) · 2026-11-21

More on this story

Report an error